Impact Investing Solutions Announces the Legacy of Impact and Love Retreat to Discover Life's Purpose
05/27/2025, Zug, Switzerland // PRODIGY: Feature Story //
This November, a rare and transformative event by Impact Investing Solutions (IIS) and BE SHIRO Foundation, is unfolding in the serene Swiss countryside, a private, weeklong ' Legacy of Impact and Love ' retreat designed specifically for seasoned investors ready to shift their capital and consciousness toward global impact. Limited to just 15 carefully selected participants, this immersive experience will take place at Kloster Fischingen, a historic monastery near the forest, from 22nd to 29th November 2025. It will offer the perfect backdrop for profound inner work and deeper personal realignment.
Behind this initiative is a forward-thinking organization with a mission to accelerate the flow of capital into meaningful, world-changing causes. Drawing from ancient meditative practices, cutting-edge AI matchmaking, and years of experience in impact investing, the retreat will help participants align their resources with their deepest values, what the organizers call going beyond impact.
Why this event? Because too many successful individuals, despite their financial achievements, still feel something is missing.
'Money doesn't make you whole,' says Sveta Banerjee, founder and CEO of IIS. 'You can have all the earthly possessions and still find yourself looking up at the stars, hoping for more. But when you look inward and realize what you truly want to bring to this world, that is what brings true fulfillment.'
This retreat is for those who have built wealth and influence but are seeking a more authentic legacy. Attendees will work closely with a handpicked team of four facilitators, including Sveta, the co-founder Ben Banerjee, alongside Andreas Dudas and Antoinette Haering of BE SHIRO, a Swiss-based cluster dedicated to empowering individuals to turn their unique life purpose into impactful change. Together, they'll guide participants through soul-centered meditations, purpose discovery, and deep conversations about how to activate philanthropic or impact capital in alignment with their true selves.
The retreat's exclusivity is deliberate. With only 15 spots available, the experience is highly personalized to ensure every participant has the space, time, and guidance to go inward and connect deeply with what truly matters.
Using refined AI matchmaking systems and insights gathered from years of working at the intersection of wealth, purpose, and social change, the team behind this initiative believes now is the time. 'We're seeing more and more investors holding back capital, not because they don't want to make a difference, but because they're still trying to decide with their heads,' says Sveta. 'This retreat helps them decide with their hearts.'
The idea behind this retreat is truly for participants to uncover their life's true mission and then channel their wealth, whether through investments or philanthropy, into causes that ignite that mission. That's how real change happens. That's how legacies are built. With a powerful team, ancient teaching, and an extraordinary setting, this retreat offers something truly unique: a bridge between wealth and purpose, between success and fulfillment.
With the retreat taking place this November and demand already building, now is the time to apply. By securing their place, individuals can solidify their place in global impact.
Media Contact:
Name: Legacy of Impact and Love Retreat Team
Email: [email protected]
Source published by Submit Press Release >> Impact Investing Solutions Announces the Legacy of Impact and Love Retreat to Discover Life's Purpose
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 hours ago
- Yahoo
Novartis Kisqali® reduces risk of recurrence in younger patients with early breast cancer in NATALEE subgroup analysis
33% reduction in relative risk of invasive disease observed in pre-menopausal early breast cancer (EBC) patients receiving Kisqali in 1-year post-treatment analysis1 Tolerability remained consistent, with fewer treatment discontinuations due to adverse events among pre-menopausal patients1 Rising breast cancer diagnosis rates and more aggressive disease in younger women underscore importance of early detection and care with effective and tolerable treatments that help prevent cancer recurrence2 Separate real-world analysis presented at ASCO demonstrates differences in treatment outcomes that underscore critical need to improve care for Black patients with EBC3 Basel, June 1, 2025 – Novartis is announcing data from a new subgroup analysis of the Phase III NATALEE trial evaluating the efficacy and safety of Kisqali® (ribociclib) plus endocrine therapy (ET, a non-steroidal aromatase inhibitor) in patients with stage II and III hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) early breast cancer (EBC) at high risk of recurrence across age and menopausal status1. The data will be presented today at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. Results at median follow-up of 44.2 months show that patients receiving Kisqali continued to see consistent reductions in risk of recurrence across all efficacy measures, regardless of age and menopausal status1. In this one-year post-treatment analysis, pre-menopausal and younger patients, who often present with more aggressive disease characteristics, experienced greater reductions in risk of recurrence and fewer treatment discontinuations due to adverse events (AEs) than post-menopausal patients1. 'As the incidence of early onset breast cancer increases, it is encouraging to see that ribociclib continues to deliver durable risk reduction for a broad population of patients with EBC, including younger patients,' said Dr. Kevin Kalinsky, Division Director of Medical Oncology and Director of the Glenn Family Breast Center at Winship Cancer Institute of Emory University. 'Coupled with the lower rates of discontinuation due to AEs seen in this subgroup, these data reinforce the benefit of three-year adjuvant treatment with ribociclib as a well-tolerated intervention for patients seeking to reduce the likelihood of their cancer coming back.' Pre-menopausal patients (n = 2238) Post-menopausal patients (n = 2844) Hazard ratioa(95% CI) AllKisqali = 1115ET = 1123 AllKisqali = 1424 ET = 1420 Invasive disease-free survival (iDFS) 0.671(0.518-0.870) 0.746(0.607-0.917) Distant disease-free survival (DDFS) 0.655(0.498-0.861) 0.759(0.612-0.941) Recurrence-free survival (RFS) 0.641(0.486-0.845) 0.735(0.588-0.919) Disposition in Kisqali arm, n (%) Discontinuation due to AE 179 (16.1) 326 (22.9) Dose reduction due to AE 248 (22.4) 332 (23.6) a Hazard ratios between treatment arms (RIB + NSAI; NSAI alone), stratified by stage, prior chemotherapy, and geographic region. Addressing Recurrence in Other At-Risk GroupsA separate real-world analysis of EBC patients who met the NATALEE trial eligibility criteria and received ET monotherapy found that Black patients were more likely to be younger, pre-menopausal, have stage III tumors, and have more extensive nodal involvement than white patients. After adjusting for these factors, Black patients also had worse RFS, DDFS, and overall survival than their white counterparts. These findings reinforce the critical need to improve care for Black patients with the addition of a CDK4/6 inhibitor to their adjuvant treatment3. Novartis is continuing to add to the body of evidence on the efficacy and safety of Kisqali in different patient populations. Trial design details will be presented at ASCO for the Adjuvant WIDER study, which is enrolling patients that closely reflect the population seen in clinical practice, including more patients from racial and ethnic minority groups4. 'There is an undeniable and urgent need to improve outcomes for vulnerable patient populations, including younger and Black patients, who often face more aggressive forms of breast cancer and remain at high risk of recurrence," said Reshema Kemps-Polanco, Executive Vice President and Chief Commercial Officer, Novartis US. "With Kisqali, we have the opportunity to reduce the risk of recurrence for these patients with early breast cancer, while we continue to offer significant survival benefit to patients living with metastatic disease.' About NATALEENATALEE is a global Phase III multi-center, randomized, open-label trial to evaluate the efficacy and safety of Kisqali with ET as an investigational adjuvant treatment versus ET alone in patients with stage II and III HR+/HER2- EBC, being conducted in collaboration with TRIO5,6. The adjuvant ET in both treatment arms was a non-steroidal aromatase inhibitor (NSAI; anastrozole or letrozole) and goserelin if applicable5,6. The primary endpoint of NATALEE is invasive disease-free survival (iDFS) as defined by the Standardized Definitions for Efficacy End Points (STEEP) criteria5,6. A total of 5,101 adult patients with HR+/HER2- EBC across 20 countries were randomized in the trial5,6. About Kisqali® (ribociclib) Kisqali® (ribociclib) is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced precision may play a role in ensuring that cancer cells do not continue to replicate uncontrollably. Kisqali has been approved as a treatment for breast cancer by regulatory authorities in 99 countries worldwide, including the U.S. FDA and the European Commission7,8. In the US, Kisqali is indicated in combination with an AI as an adjuvant treatment for adults with HR+/HER2- stage II and III early breast cancer at high risk of recurrence, as well as for the treatment of adults with HR+/HER2- advanced or MBC as initial ET; Kisqali is also approved in the metastatic indication in combination with fulvestrant as initial ET or following disease progression on ET7. In the EU, Kisqali is approved in combination with an AI for the adjuvant treatment of patients with HR+/HER2- early breast cancer at high risk of recurrence; and for the treatment of women with HR+/HER2- advanced or MBC in combination with either an AI or fulvestrant as initial ET or following disease progression8. In pre- or peri-menopausal women, the ET should be combined with a luteinizing hormone-releasing hormone agonist7,8. In EBC, ribociclib (Kisqali) is the only CDK4/6 inhibitor recommended by the NCCN Guidelines® for breast cancer for both all node-positive disease as well as for patients with no nodal involvement with high-risk disease characteristics, such as tumor size >5 cm, or for tumors sized 2-5 cm, either Grade 2 with high genomic risk/Ki-67 ≥20% or Grade 39. Kisqali approvals in EBC from regulatory authorities worldwide are ongoing, including recent approval from China's National Medical Products Administration10. In MBC, Kisqali has consistently demonstrated statistically significant overall survival benefit across three Phase III trials11-21. The NCCN Guidelines® also recommend ribociclib (Kisqali) as the only Category 1 preferred CDK4/6 inhibitor for first-line treatment of people living with HR+/HER2- MBC when combined with an AI9, making Kisqali the preferred first-line treatment of choice for US prescribers in HR+/HER2- MBC. In addition, Kisqali has achieved the highest score (A) on the European Society for Medical Oncology-Magnitude of Clinical Benefit Scale (ESMO-MCBS) for EBC22; and has the highest rating of any CDK4/6 inhibitor on the ESMO Magnitude of Clinical Benefit Scale, achieving a score of five out of five for first-line pre-menopausal patients with HR+/HER2- advanced breast cancer23. Further, Kisqali in combination with either letrozole or fulvestrant has uniquely, among other CDK4/6 inhibitors, received a score of four out of five for post-menopausal patients with HR+/HER2- advanced breast cancer treated in the first line24. Kisqali was developed by Novartis under a research collaboration with Astex Pharmaceuticals. Please see full Prescribing Information for Kisqali, available at About Novartis in Breast CancerFor more than 30 years, Novartis has been at the forefront of driving scientific advancements for people touched by breast cancer and improving clinical practice in collaboration with the global community. With one of the most comprehensive breast cancer portfolios and pipeline, Novartis leads the industry in the discovery of new therapies and combinations in HR+/HER2- breast cancer, the most common form of the disease. Beyond medicines, Novartis is leading efforts to encourage early detection and working to remove access barriers faced by patients along their care journey. DisclaimerThis press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as 'potential,' 'can,' 'will,' 'plan,' 'may,' 'could,' 'would,' 'expect,' 'anticipate,' 'look forward,' 'believe,' 'committed,' 'investigational,' 'pipeline,' 'launch,' or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the investigational or approved products described in this press release, or regarding potential future revenues from such products. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise. About Novartis Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people's lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach nearly 300 million people worldwide. Reimagine medicine with us: Visit us at and connect with us on LinkedIn, Facebook, X/Twitter and Instagram. References Kalinsky K et al. Efficacy and safety of ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) in NATALEE: Analysis across menopausal status and age. Presented at the American Society of Clinical Oncology Annual Meeting, June 1, 2025. Chicago, USA. American Cancer Society. Cancer Facts & Figures 2025. American Cancer Society. 2025. Available from: Accessed May 2025. Abdou Y et al. Real-world (RW) analysis of characteristics and risk of recurrence (ROR) in Black patients (pts) with HR+/HER2- early breast cancer (EBC) eligible for NATALEE. Presented at the American Society of Clinical Oncology Annual Meeting, June 2, 2025. Chicago, USA. Graff SL et al. Adjuvant WIDER: A phase 3b trial of ribociclib (RIB) + endocrine therapy (ET) as adjuvant treatment (tx) in a close-to-clinical-practice patient (pt) population with HR+/HER2− early breast cancer (EBC). Presented at the American Society of Clinical Oncology Annual Meeting. June 2, 2025. Chicago, USA. Slamon D, Lipatov O, Nowecki Z, et al. Ribociclib plus Endocrine Therapy in Early Breast Cancer. N Engl J Med. 2024;390(12):1080-1091. doi:10.1056/NEJMoa2305488 NCT03701334. A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/ HER2- Early Breast Cancer (NATALEE). Available from: Accessed May 2025. Kisqali. Prescribing Information (US FDA). Novartis Pharmaceuticals Corporation; 2017. Accessed May 2025. Kisqali. Summary of product characteristics (SmPC). Novartis Europharm Limited; 2017. Accessed May 2025. NCCN Guidelines. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) - Breast Cancer. Accessed May 2025. National Medical Products Administration. Drug Evaluation Information Disclosure: Drug Evaluation Approval Results. National Medical Products Administration. Published May 21, 2025. Accessed May 28, 2025. Yardley DA et al. Pooled exploratory analysis of survival in patients (pts) with HR+/HER2- advanced breast cancer (ABC) and visceral metastases (mets) treated with ribociclib (RIB) + endocrine therapy (ET) in the MONALEESA (ML) trials. Poster presented at the European Society of Medical Oncology Congress. September 9-13, 2022. Paris, France. Neven P et al. Updated overall survival (OS) results from the first-line (1L) population in the Phase III MONALEESA-3 trial of postmenopausal patients with HR+/HER2- advanced breast cancer (ABC) treated with ribociclib (RIB) + fulvestrant (FUL). Mini oral presented at the European Society for Medical Oncology Breast Cancer Congress. May 4, 2022. Paris, France. Hortobagyi GN, Stemmer SM, Burris HA, et al. Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer. N Engl J Med. 2022;386(10):942-950. doi:10.1056/NEJMoa2114663 Hortobagyi GN et al. Overall survival (OS) results from the phase III MONALEESA (ML)-2 trial of postmenopausal patients with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2−) advanced breast cancer (ABC) treated with endocrine therapy (ET) ± ribociclib. LBA 17. Proffered paper presented at the European Society of Medical Oncology Congress, September 16-21, 2021. Lugano, Switzerland. Im SA, Lu YS, Bardia A, et al. Overall survival with ribociclib plus endocrine therapy in breast cancer. N Engl J Med. 2019;381(4):307-316. doi:10.1056/NEJMoa1903765 Slamon DJ, Neven P, Chia S, et al. Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer. N Engl J Med. 2020;382(6):514-524. doi:10.1056/NEJMoa1911149 Slamon DJ et al. Overall survival (OS) results of the Phase III MONALEESA-3 trial of postmenopausal patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor 2-negative (HER2-) advanced breast cancer (ABC) treated with fulvestrant (FUL) ± ribociclib (RIB). LBA7_PR. Presented at the European Society of Medical Oncology Congress, September 29, 2019. Barcelona, Spain. Slamon DJ et al. Updated overall survival (OS) results from the Phase III MONALEESA-3 trial of postmenopausal patients (pts) with HR+/HER2− advanced breast cancer (ABC) treated with fulvestrant (FUL) ± ribociclib (RIB). Presented at the American Society of Clinical Oncology Annual Meeting, June 5, 2021. Chicago, USA. Tripathy D et al. Updated overall survival (OS) results from the phase III MONALEESA-7 trial of pre- or perimenopausal patients with HR+/HER2− advanced breast cancer (ABC) treated with endocrine therapy (ET) ± ribociclib. Presented at the San Antonio Breast Cancer Symposium, December 9, 2020. Texas, USA. Yardley D et al. Overall survival (OS) in patients (pts) with advanced breast cancer (ABC) with visceral metastases (mets), including those with liver mets, treated with ribociclib (RIB) plus endocrine therapy (ET) in the MONALEESA (ML) -3 and -7 trials. Presented at the American Society of Clinical Oncology Annual Meeting, June 2020. Chicago, USA. O'Shaughnessy J et al. Overall survival subgroup analysis by metastatic site from the Phase III MONALEESA-2 study of first-line ribociclib + letrozole in postmenopausal patients with HR+/HER2− advanced breast cancer. Presented at the San Antonio Breast Cancer Symposium, December 7-10, 2021. Texas, USA. European Society of Medical Oncology (ESMO). ESMO MCBS scorecards; NATALEE. Accessed May 2025. European Society for Medical Oncology. Magnitude of Clinical Benefit Scale Scorecard. Accessed May 2025. European Society for Medical Oncology. Magnitude of Clinical Benefit Scale Scorecard. Accessed May 2025. # # # Novartis Media Relations E-mail: Novartis Investor Relations Central investor relations line: +41 61 3247944 E-mail: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
4 hours ago
- Yahoo
Scientists Create Biodegradable Plastic Alternative That's Literally Alive
Swiss scientists have created a new plastic-like material that's flexible, biodegradable, and even edible. The secret? It's still alive. The material, which was created by a team from Empa in Switzerland, manages to balance biodegradability with toughness and versatility – a feat that is far from easy in materials science. The researchers processed fibers from the mycelium (the root-like part) of the split-gill mushroom (Schizophyllum commune) into a liquid mixture, without actually killing them off or destroying their natural biological functions. The resulting gel-like material is called living fiber dispersions, or LFD, and it can be molded into many different forms. It also makes full use of the extra substances produced by mushrooms, where other biomaterials might just use the core fungal cells. "The fungus uses this extracellular matrix to give itself structure and other functional properties," says materials scientist Ashutosh Sinha, from Empa. "Why shouldn't we do the same?" By developing a specific strain of the split-gill, the researchers were able to encourage the growth of two molecules in particular: polysaccharide schizophyllan and hydrophobin. These molecules are crucial in giving LFD its appealing properties. One possible use of the material is as a thin film with a very high tensile strength. The researchers suggest it could potentially be used in compost bags that naturally rot away as well as composting their contents, or in super-thin biodegradable batteries. LFD also works well as an emulsifier, a substance that enables two other materials to mix and bind together when they otherwise wouldn't. Emulsifiers are important in food and cosmetics production, found in everything from ice cream to shampoo. Because it's still alive, the fungus keeps releasing more of its key molecules. "This is probably the only type of emulsion that becomes more stable over time," says Sinha. And because it comes from the edible S. commune mushroom, this LFD is completely non-toxic too – you can even eat it without any problems. When it comes to foods and cosmetics, that's another big plus for the material. There's the potential for plenty of future research here too, because the team thinks that the approach used here could be tweaked to produce materials with other specific properties, like an on-demand materials maker. Scientists will often look to nature for inspiration, whether they're developing drug delivery methods or building robots, and we're seeing an increasing number of studies investigating fungi as a foundation for new materials. Fungi-based biomaterials could act as alternatives to plastic, and to form clothes that are able to repair themselves. There's a lot of benefit in materials that combine the natural and the synthetic. The researchers are hoping to find more and more practical uses for LFD over time, following in a long line of materials inspired by nature – evidence that the natural world around us is the best lab there is. "Biodegradable materials always react to their environment," says materials scientist Gustav Nyström, from Empa. "We want to find applications where this interaction is not a hindrance but maybe even an advantage." The research has been published in Advanced Materials. Uploading The Human Mind Could Become a Reality, Expert Says Scientists Developed a Kind of 'Living Concrete' That Heals Its Own Cracks World's First CRISPR-Edited Spiders Shoot Fluoro Red Silk From Their Butts
Yahoo
7 hours ago
- Yahoo
Estimating The Fair Value Of Burckhardt Compression Holding AG (VTX:BCHN)
Burckhardt Compression Holding's estimated fair value is CHF739 based on 2 Stage Free Cash Flow to Equity With CHF610 share price, Burckhardt Compression Holding appears to be trading close to its estimated fair value The CHF716 analyst price target for BCHN is 3.1% less than our estimate of fair value How far off is Burckhardt Compression Holding AG (VTX:BCHN) from its intrinsic value? Using the most recent financial data, we'll take a look at whether the stock is fairly priced by estimating the company's future cash flows and discounting them to their present value. We will use the Discounted Cash Flow (DCF) model on this occasion. Before you think you won't be able to understand it, just read on! It's actually much less complex than you'd imagine. We generally believe that a company's value is the present value of all of the cash it will generate in the future. However, a DCF is just one valuation metric among many, and it is not without flaws. If you still have some burning questions about this type of valuation, take a look at the Simply Wall St analysis model. Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. We are going to use a two-stage DCF model, which, as the name states, takes into account two stages of growth. The first stage is generally a higher growth period which levels off heading towards the terminal value, captured in the second 'steady growth' period. To begin with, we have to get estimates of the next ten years of cash flows. Where possible we use analyst estimates, but when these aren't available we extrapolate the previous free cash flow (FCF) from the last estimate or reported value. We assume companies with shrinking free cash flow will slow their rate of shrinkage, and that companies with growing free cash flow will see their growth rate slow, over this period. We do this to reflect that growth tends to slow more in the early years than it does in later years. Generally we assume that a dollar today is more valuable than a dollar in the future, and so the sum of these future cash flows is then discounted to today's value: 2025 2026 2027 2028 2029 2030 2031 2032 2033 2034 Levered FCF (CHF, Millions) CHF33.8m CHF82.8m CHF96.0m CHF105.3m CHF112.5m CHF118.0m CHF122.3m CHF125.5m CHF128.0m CHF129.9m Growth Rate Estimate Source Analyst x2 Analyst x2 Analyst x2 Est @ 9.64% Est @ 6.87% Est @ 4.94% Est @ 3.58% Est @ 2.63% Est @ 1.97% Est @ 1.50% Present Value (CHF, Millions) Discounted @ 5.1% CHF32.2 CHF75.0 CHF82.8 CHF86.4 CHF87.9 CHF87.8 CHF86.6 CHF84.6 CHF82.1 CHF79.3 ("Est" = FCF growth rate estimated by Simply Wall St)Present Value of 10-year Cash Flow (PVCF) = CHF785m We now need to calculate the Terminal Value, which accounts for all the future cash flows after this ten year period. For a number of reasons a very conservative growth rate is used that cannot exceed that of a country's GDP growth. In this case we have used the 5-year average of the 10-year government bond yield (0.4%) to estimate future growth. In the same way as with the 10-year 'growth' period, we discount future cash flows to today's value, using a cost of equity of 5.1%. Terminal Value (TV)= FCF2034 × (1 + g) ÷ (r – g) = CHF130m× (1 + 0.4%) ÷ (5.1%– 0.4%) = CHF2.8b Present Value of Terminal Value (PVTV)= TV / (1 + r)10= CHF2.8b÷ ( 1 + 5.1%)10= CHF1.7b The total value, or equity value, is then the sum of the present value of the future cash flows, which in this case is CHF2.5b. The last step is to then divide the equity value by the number of shares outstanding. Relative to the current share price of CHF610, the company appears about fair value at a 17% discount to where the stock price trades currently. Remember though, that this is just an approximate valuation, and like any complex formula - garbage in, garbage out. We would point out that the most important inputs to a discounted cash flow are the discount rate and of course the actual cash flows. Part of investing is coming up with your own evaluation of a company's future performance, so try the calculation yourself and check your own assumptions. The DCF also does not consider the possible cyclicality of an industry, or a company's future capital requirements, so it does not give a full picture of a company's potential performance. Given that we are looking at Burckhardt Compression Holding as potential shareholders, the cost of equity is used as the discount rate, rather than the cost of capital (or weighted average cost of capital, WACC) which accounts for debt. In this calculation we've used 5.1%, which is based on a levered beta of 1.071. Beta is a measure of a stock's volatility, compared to the market as a whole. We get our beta from the industry average beta of globally comparable companies, with an imposed limit between 0.8 and 2.0, which is a reasonable range for a stable business. View our latest analysis for Burckhardt Compression Holding Strength Earnings growth over the past year exceeded the industry. Debt is not viewed as a risk. Weakness Earnings growth over the past year is below its 5-year average. Dividend is low compared to the top 25% of dividend payers in the Machinery market. Opportunity Annual revenue is forecast to grow faster than the Swiss market. Current share price is below our estimate of fair value. Threat Dividends are not covered by cash flow. Annual earnings are forecast to grow slower than the Swiss market. Whilst important, the DCF calculation ideally won't be the sole piece of analysis you scrutinize for a company. It's not possible to obtain a foolproof valuation with a DCF model. Rather it should be seen as a guide to "what assumptions need to be true for this stock to be under/overvalued?" For example, changes in the company's cost of equity or the risk free rate can significantly impact the valuation. For Burckhardt Compression Holding, there are three important aspects you should consider: Risks: Consider for instance, the ever-present spectre of investment risk. We've identified 1 warning sign with Burckhardt Compression Holding , and understanding this should be part of your investment process. Future Earnings: How does BCHN's growth rate compare to its peers and the wider market? Dig deeper into the analyst consensus number for the upcoming years by interacting with our free analyst growth expectation chart. Other Solid Businesses: Low debt, high returns on equity and good past performance are fundamental to a strong business. Why not explore our interactive list of stocks with solid business fundamentals to see if there are other companies you may not have considered! PS. Simply Wall St updates its DCF calculation for every Swiss stock every day, so if you want to find the intrinsic value of any other stock just search here. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
